Assessment of Data Supporting the Efficacy of New Antibiotics for Treating Infections Caused by Multidrug-resistant Bacteria
Clicks: 67
ID: 268705
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
19.8
/100
67 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #884 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
FDA approvals of new drugs with in-vitro activity against MDR bacteria are supported by non-inferiority trials, addressing common infections regardless of causa
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (22 words).
Try re-searching for a better abstract.
| Reference Key |
dafna2021clinicalassessment
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yahav, Dafna;Tau, Noam;Shepshelovich, Daniel; |
| Journal | clinical infectious diseases |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.